JP2003508467A5 - - Google Patents

Download PDF

Info

Publication number
JP2003508467A5
JP2003508467A5 JP2001521170A JP2001521170A JP2003508467A5 JP 2003508467 A5 JP2003508467 A5 JP 2003508467A5 JP 2001521170 A JP2001521170 A JP 2001521170A JP 2001521170 A JP2001521170 A JP 2001521170A JP 2003508467 A5 JP2003508467 A5 JP 2003508467A5
Authority
JP
Japan
Prior art keywords
composition according
weight
inhibitor
alpha
absorption
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2001521170A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003508467A (ja
Filing date
Publication date
Priority claimed from GBGB9921229.2A external-priority patent/GB9921229D0/en
Application filed filed Critical
Publication of JP2003508467A publication Critical patent/JP2003508467A/ja
Publication of JP2003508467A5 publication Critical patent/JP2003508467A5/ja
Withdrawn legal-status Critical Current

Links

JP2001521170A 1999-09-08 2000-09-08 アルファ−アミラーゼインヒビターと、腸からの「速効性糖類(fastsugars)」の吸収を減少させるために適する少なくとも一種類の生理学的に許容可能な化合物とを含む組成物 Withdrawn JP2003508467A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9921229.2 1999-09-08
GBGB9921229.2A GB9921229D0 (en) 1999-09-08 1999-09-08 Compositions
PCT/GB2000/003472 WO2001017369A1 (en) 1999-09-08 2000-09-08 Composition comprising an alpha-amylase inhibitor and at least one physiologically acceptable compound capable of reducing intestinal absorption of 'fast sugars'

Publications (2)

Publication Number Publication Date
JP2003508467A JP2003508467A (ja) 2003-03-04
JP2003508467A5 true JP2003508467A5 (cg-RX-API-DMAC7.html) 2007-10-11

Family

ID=10860574

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001521170A Withdrawn JP2003508467A (ja) 1999-09-08 2000-09-08 アルファ−アミラーゼインヒビターと、腸からの「速効性糖類(fastsugars)」の吸収を減少させるために適する少なくとも一種類の生理学的に許容可能な化合物とを含む組成物

Country Status (14)

Country Link
EP (1) EP1213972B1 (cg-RX-API-DMAC7.html)
JP (1) JP2003508467A (cg-RX-API-DMAC7.html)
KR (1) KR100594520B1 (cg-RX-API-DMAC7.html)
AT (1) ATE238689T1 (cg-RX-API-DMAC7.html)
AU (1) AU777044B2 (cg-RX-API-DMAC7.html)
CA (1) CA2383720A1 (cg-RX-API-DMAC7.html)
DE (1) DE60002484T2 (cg-RX-API-DMAC7.html)
DK (1) DK1213972T3 (cg-RX-API-DMAC7.html)
ES (1) ES2199174T3 (cg-RX-API-DMAC7.html)
GB (2) GB9921229D0 (cg-RX-API-DMAC7.html)
NO (1) NO314922B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ518167A (cg-RX-API-DMAC7.html)
PT (1) PT1213972E (cg-RX-API-DMAC7.html)
WO (1) WO2001017369A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601528B1 (en) 2000-12-23 2009-10-13 Elan Pharmaceuticals, Inc. Crystallization and structure determination of glycosylated human beta secretase, an enzyme implicated in alzheimer's disease
US7217556B1 (en) 2000-12-23 2007-05-15 Pfizer Inc Crystallization and structure determination of glycosylated human beta secretase, an enzyme implicated in Alzheimer's disease
US7384773B1 (en) 2001-05-10 2008-06-10 Pfizer Inc Crystal of HIV protease-cleaved human beta secretase and method for crystallization thereof
US6797287B2 (en) 2001-09-25 2004-09-28 Pharmachem Laboratories, Inc. Phaseolamin compositions and methods for using the same
US7108869B2 (en) 2002-11-07 2006-09-19 Access Business Group International Llc Nutritional supplement containing alpha-glucosidase and alpha-amylase inhibitors
ITMI20030391A1 (it) * 2003-03-04 2004-09-05 S I I T S R L Servizio Internaz Ionale Imballa Formulazioni anticarie a base di faseolamina.
ITMI20052450A1 (it) * 2005-12-22 2007-06-23 Indena Spa Estratti di phaseolus vulgaris loro uso e formulazioni che li contengono
JP5285852B2 (ja) * 2006-12-28 2013-09-11 株式会社ファンケル Dfaiiiの製造方法及びdfaiii高含有植物エキス
US20100330137A1 (en) * 2008-03-10 2010-12-30 Mauro Mantovani High bioavailability formulation of mangosteen and manufacturing process thereof
CN102292093B (zh) * 2009-02-02 2015-01-28 莱拉营养食品有限公司 用于代谢综合症控制的选自绒毛戴星草和莽吉柿的混合物
JP2011079752A (ja) * 2009-10-05 2011-04-21 Kracie Home Products Ltd 膵リパーゼ阻害剤並びにそれを含有する飲食品組成物及び医薬品組成物
CN103478738B (zh) * 2013-09-17 2016-02-10 深圳太太药业有限公司 一种具有减肥塑身及体重管理作用的组合物
EP3193899A1 (en) * 2014-09-19 2017-07-26 Nestec S.A. Methods and formulations for reducing absorption of carbohydrates in a companion animal
CN106036342A (zh) * 2016-06-14 2016-10-26 安徽平唐微食疗科技有限公司 适合于糖尿病人群食用的膳食补充固体饮料及其制备方法
IT201700078389A1 (it) * 2017-07-13 2019-01-13 Mv Medical Solutions Composizione utile nella prevenzione o trattamento degli stati di malassorbimento secondari a chirurgia bariatrica in soggetti obesi.
EP3975755A1 (en) * 2019-05-24 2022-04-06 Cosucra Groupe Warcoing S.A. Composition comprising inulin and protein

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4010258A (en) * 1974-03-15 1977-03-01 Ajinomoto Co., Inc. Microbial amylase inhibitor and preparation thereof with the use of streptomyces diasticus var. amylostaticus
JP2757405B2 (ja) * 1988-12-09 1998-05-25 日清製粉株式会社 小麦から得られるα−アミラーゼインヒビターを含有するダイエット剤
US5612039A (en) * 1994-03-14 1997-03-18 Nini E. Policappelli Dietary supplement
JP2002535288A (ja) * 1999-01-22 2002-10-22 ウンツァ ディ マリア カルメラ マラッツィータ エッセ.ア.エッセ. リポタンパク質複合体およびそれらを含む組成物

Similar Documents

Publication Publication Date Title
SG170119A1 (en) Nutritional composition comprising indigestible oligosaccharides
EP2283826A3 (en) Galenic formulations of organic compounds
DE60131703D1 (de) Orale feste pharmazeutische Zusammensetzungen zur pH-abhängig mehrphasigen Freisetzung
BR0115910A (pt) Compostos orgânicos
WO2004012700A3 (en) Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release
JP2006516648A5 (cg-RX-API-DMAC7.html)
NO20062513L (no) Sammensetninger og doseringsformer for forsterket absorpsjon av metformin
JP2008525445A5 (cg-RX-API-DMAC7.html)
JP2004519488A5 (cg-RX-API-DMAC7.html)
JP2010513487A5 (cg-RX-API-DMAC7.html)
WO2001092283A3 (en) Cobalamin compounds useful as cardiovascular agents and as imaging agents
JPH10114649A5 (cg-RX-API-DMAC7.html)
WO2007046867A3 (en) Piperidine derivatives and their uses as therapeutic agents
RU2006121995A (ru) Композиция и способ
CA2389032A1 (en) Preventive or therapeutic agents for inflammatory diseases of intestine
JP2006511538A5 (cg-RX-API-DMAC7.html)
JP2009518415A5 (cg-RX-API-DMAC7.html)
WO2004071156A3 (en) Use of edible acid in fast-dispersing pharmaceutical solid dosage forms
JP2009515927A5 (cg-RX-API-DMAC7.html)
NO20021160L (no) Bestanddeler
JP2008515980A5 (cg-RX-API-DMAC7.html)
JP2002537232A5 (cg-RX-API-DMAC7.html)
JP2008542297A5 (cg-RX-API-DMAC7.html)
WO2004096125A3 (en) Pharmaceutical compositions releasing their active agents from a buccal or sublingual location to overcome an absorption window problem
ES2344909T3 (es) Nuevas combinaciones de un antagonista del receptor 5-ht3 con racecadotril o dexecanotril.